These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 17721976)

  • 1. Protein isolated from biopharmaceutical formulations cannot be used for comparative studies: Follow-up to "a case study using Epoetin Alfa from Epogen and EPREX".
    Heavner GA; Arakawa T; Philo JS; Calmann MA; Labrenz S
    J Pharm Sci; 2007 Dec; 96(12):3214-25. PubMed ID: 17721976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biophysical comparability of the same protein from different manufacturers: a case study using Epoetin alfa from Epogen and Eprex.
    Deechongkit S; Aoki KH; Park SS; Kerwin BA
    J Pharm Sci; 2006 Sep; 95(9):1931-43. PubMed ID: 16850392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: a randomized prospective study.
    Lissy M; Ode M; Roth K
    Drugs R D; 2011; 11(1):61-75. PubMed ID: 21410296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity.
    Seidl A; Hainzl O; Richter M; Fischer R; Böhm S; Deutel B; Hartinger M; Windisch J; Casadevall N; London GM; Macdougall I
    Pharm Res; 2012 Jun; 29(6):1454-67. PubMed ID: 22094831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Micelle-associated protein in epoetin formulations: aA risk factor for immunogenicity?
    Hermeling S; Schellekens H; Crommelin DJ; Jiskoot W
    Pharm Res; 2003 Dec; 20(12):1903-7. PubMed ID: 14725351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical assessment of erythropoietin products from Asia versus US Epoetin alfa manufactured by Amgen.
    Park SS; Park J; Ko J; Chen L; Meriage D; Crouse-Zeineddini J; Wong W; Kerwin BA
    J Pharm Sci; 2009 May; 98(5):1688-99. PubMed ID: 18781649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability of multidose, preserved formulation epoetin alfa in syringes for three and six weeks.
    Naughton CA; Duppong LM; Forbes KD; Sehgal I
    Am J Health Syst Pharm; 2003 Mar; 60(5):464-8. PubMed ID: 12635452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The oxidation of methionine-54 of epoetinum alfa does not affect molecular structure or stability, but does decrease biological activity.
    Labrenz SR; Calmann MA; Heavner GA; Tolman G
    PDA J Pharm Sci Technol; 2008; 62(3):211-23. PubMed ID: 18661870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reaction to the paper: interaction of polysorbate 80 with erythropoietin: a case study in protein-surfactant interactions.
    Hermeling S; Jiskoot W; Crommelin DJ; Schellekens H
    Pharm Res; 2006 Mar; 23(3):641-2; author reply 643-4. PubMed ID: 16525860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of illegal trade on the quality of epoetin alfa in Thailand.
    Fotiou F; Aravind S; Wang PP; Nerapusee O
    Clin Ther; 2009 Feb; 31(2):336-46. PubMed ID: 19302906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial on the therapeutic equivalence between Eprex and GerEPO in patients on haemodialysis.
    Goh BL; Ong LM; Sivanandam S; Lim TO; Morad Z;
    Nephrology (Carlton); 2007 Oct; 12(5):431-6. PubMed ID: 17803464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recognition and identification of UV-absorbing leachables in EPREX pre-filled syringes: an unexpected occurrence at a formulation-component interface.
    Pang J; Blanc T; Brown J; Labrenz S; Villalobos A; Depaolis A; Gunturi S; Grossman S; Lisi P; Heavner GA
    PDA J Pharm Sci Technol; 2007; 61(6):423-32. PubMed ID: 18410043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of polysorbate 80 with erythropoietin: a case study in protein-surfactant interactions.
    Villalobos AP; Gunturi SR; Heavner GA
    Pharm Res; 2005 Jul; 22(7):1186-94. PubMed ID: 16028020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization and qualification of capillary zone electrophoresis method for glycoprotein isoform distribution of erythropoietin for quality control laboratory.
    Zhang J; Chakraborty U; Villalobos AP; Brown JM; Foley JP
    J Pharm Biomed Anal; 2009 Oct; 50(3):538-43. PubMed ID: 19515523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pure red-cell aplasia and epoetin therapy.
    Bennett CL; Luminari S; Nissenson AR; Tallman MS; Klinge SA; McWilliams N; McKoy JM; Kim B; Lyons EA; Trifilio SM; Raisch DW; Evens AM; Kuzel TM; Schumock GT; Belknap SM; Locatelli F; Rossert J; Casadevall N
    N Engl J Med; 2004 Sep; 351(14):1403-8. PubMed ID: 15459301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and biosimilarity of ior(®) EPOCIM compared with Eprex(®) based on toxicologic, pharmacodynamic, and pharmacokinetic studies in the Sprague-Dawley rat.
    Pucaj K; Riddle K; Taylor SR; Ledon N; Bolger GT
    J Pharm Sci; 2014 Nov; 103(11):3432-3441. PubMed ID: 25250536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another.
    Macdougall IC
    Curr Med Res Opin; 2004 Jan; 20(1):83-6. PubMed ID: 14741076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality and Batch-to-Batch Consistency of Original and Biosimilar Epoetin Products.
    Halim LA; Brinks V; Jiskoot W; Romeijn S; Haselberg R; Burns C; Wadhwa M; Schellekens H
    J Pharm Sci; 2016 Feb; 105(2):542-550. PubMed ID: 26869417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the bioequivalence of two formulations of epoetin alfa after subcutaneous injection.
    Togawa A; Tanaka T; Nagashima S; Keta H; Kobayashi Y; Nishikawa Y; Yanai M; Tanaka H
    Br J Clin Pharmacol; 2004 Sep; 58(3):269-76. PubMed ID: 15327586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the immuno-stimulatory potential of stopper extractables and leachables by using dendritic cells as readout.
    Mueller R; Karle A; Vogt A; Kropshofer H; Ross A; Maeder K; Mahler HC
    J Pharm Sci; 2009 Oct; 98(10):3548-61. PubMed ID: 19226629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.